Antisense oligonucleotides to c-kit proto-oncogene and uses thereof
CA 2107915 A1 · Owner: Temple University Of The Commonwealth System Of Higher Education · Inventors: Calabretta, Bruno; Gewirtz, Alan M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-kit gene. These "antisense" oligonucleotides are hybridizable to the c-kit mRNA transcript. Such oligonucleotides are useful in selectively inhibiting proliferation of erythroid cells particularly in disorders characterized by an elevated hematocrit due to overproduction of erythrocytes. The antisense oligomers also have activity agent hematologic neoplastic cells and are therefore suitable as bone marrow purging agents.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 8, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 8, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 8, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.